Company Profile
Beijing Biostar Pharmaceuticals Co., Ltd., a synthetic biology-driven biopharmaceutical company provides the development, manufacturing, and commercialization of oncology products in the People's Republic of China.
The company develops Utidelone injections for metastatic breast cancer, breast cancer neoadjuvant, non-small cell lung cancer, pancreatic cancer, non-small cell lung cancer brain metastasis, and breast cancer brain metastasis indications
Utidelone capsules for metastasis breast cancer, triple-negative breast cancer adjuvant intensive, first line gastric cancer, platinum-resistant ovarian cancer, and soft tissue sarcoma indications.
It is also involved in the development of Utidelone antibody drug conjugate in preclinical studies; and BG22, BG18, and BG44 products for solid tumor indications in preclinical studies. Incorporated in 2002, Beijing Biostar Pharmaceuticals is headquartered in Beijing, China.